KeepItRealistic
2時間前
$OSRH using AI to help read between the lines of last PR
https://finviz.com/news/359385/ceo-statement-to-shareholders
OSR Holdings (NASDAQ: OSRH) is a small-cap hub-and-spoke biotech/ healthcare holding company with a diversified portfolio of subsidiaries focused on immuno-oncology (especially VXM01), regenerative biologics, noninvasive glucose monitoring (Woori IO, with Samsung ties), and medical device distribution.
The “Value Creation Framework” section in the recent CEO shareholder letter (June 3, 2026) is a classic holding-company signaling language. It explicitly highlights tools like thoughtful capital allocation, strategic partnerships, subsidiary monetizations, spin-offs, and other corporate actions common in public hub-and-spoke biotech structures. They are not announcing anything specific yet, but are “evaluating a full range of tools.”
What the company is likely working on:
• Unlocking value from key assets, especially VXM01 — This oral DNA-based immunotherapy (targeting VEGFR-2 for cancers like glioblastoma) is their flagship. They recently centralized full IP ownership at the parent level via a $30M asset purchase, alongside a major licensing deal with BCM Europe AG (up to $815M in milestones + royalties structured to flow to OSRH shareholders). This setup gives them flexibility for further partnering, sublicensing, royalty monetization, or other structures.
• Similar actions across the portfolio — Other assets include design-augmented biologics (e.g., for spinal fusion/osteoarthritis) and the noninvasive glucose monitor.
The letter specifically calls out ongoing progress with Woori IO and Samsung engagements.
• Corporate transactions to address valuation and compliance — As a micro-cap (~$14-15M market cap) trading near its 52-week low and dealing with Nasdaq minimum bid price compliance, spin-offs or monetizations of mature/specific subsidiaries could let the market value assets more directly (a common play in biotech holdings to narrow the “conglomerate discount”). This also supports Nasdaq listing maintenance without a reverse split (which the CEO has previously downplayed).
In short, they are almost certainly preparing or actively shopping one or more subsidiaries/assets for partnerships, licensing expansions, spin-offs, or partial monetizations. The language is preparatory and reassures shareholders that management is focused on value-unlocking moves rather than just operations. This is typical for holding companies with promising but capital-intensive biotech assets in a tough small-cap environment.
It’s bullish signaling if they execute well (e.g., big pharma partnerships for VXM01 or a clean spin).
US Market News
3日前
CEO Statement to ShareholdersJune 3, 2026 12:05 PM
ACCESS NewswireBELLEVUE, WA / ACCESS Newswire / June 3, 2026 / Dear Fellow Shareholders,As we move through 2026, I would like to provide an update on where OSR Holdings (NASDAQ:OSRH) stands today and how we are approaching the opportunities ahead:Strategic Focus and Business DevelopmentOver the past year, we have continued to strengthen our position as a biomedical holding company with a growing portfolio of innovative businesses spanning oncology, regenerative medicine, medical devices, and digital health. We are seeing increasing external validation of the technologies and platforms being developed by our subsidiaries.Vaximm recently executed a definitive licensing agreement for the VXM01 immunotherapy platform, one of the most significant transactions in the Company's history. At Woori IO, development activities and strategic engagements involving global industry participants, including Samsung, continue to advance our noninvasive glucose monitoring platform.Across our portfolio, we are focused on transforming scientific innovation into commercial opportunities and long-term shareholder value.Value Creation FrameworkAs a holding company, our responsibility is to continually evaluate how best to unlock the value of our underlying businesses for the benefit of shareholders. Public markets have repeatedly demonstrated that significant value can be created through thoughtful capital allocation, strategic partnerships, subsidiary monetizations, spin-offs, and other corporate actions that allow investors to participate more directly in the success of underlying assets.While we are not announcing any specific transaction at this time, I can assure shareholders that we are evaluating a full range of tools available to publicly listed Hub-and-Spoke biotech companies and are committed to pursuing opportunities that we believe will benefit our investors.Nasdaq Compliance UpdateWe continue to work closely with Nasdaq, our advisors, and industry experts regarding our minimum bid price compliance process. Maintaining a Nasdaq listing remains an important objective, and we are evaluating pathways to achieve compliance while preserving and enhancing long-term shareholder value.Our focus remains on building sustainable businesses, advancing technologies, creating partnerships, and positioning OSRH to unlock value over time.OutlookThe next chapter of OSRH will not be defined by a compliance deadline or short-term considerations such as the next quarter or month, but by its ability to translate scientific innovation into enduring shareholder value.We remain confident in our portfolio, our partners, and the opportunities before us, and we appreciate the continued trust and support of our shareholders as we execute our strategy.Sincerely,Peter Hwang
Chief Executive Officer
OSR Holdings, Inc.About OSR Holdings, Inc.OSR Holdings, Inc. (NASDAQ:OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in health and wellness. Through its subsidiaries, OSR Holdings engages in immuno-oncology, regenerative biologics, and medical device technologies to improve health outcomes worldwide. Learn more at www.OSR-Holdings.com.Investor ContactOSR Holdings, Inc.
Investor Relations
ir@osr-holdings.comForward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Nasdaq compliance, strategic transactions, commercialization initiatives, and future business developments. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. OSR Holdings undertakes no obligation to update these statements except as required by law.SOURCE: OSR Holdings, Inc.View the original press release on ACCESS NewswireOriginal: CEO Statement to Shareholders
US Market News
1週前
OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million TransactionMay 27, 2026 9:06 AM
ACCESS NewswireTransaction Centralizes VXM01 Ownership and Long-Term Royalty Economics at the OSRH Parent LevelBELLEVUE, WA / ACCESS Newswire / May 27, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding company focused on innovative therapeutics and healthcare technologies, today announced it has entered into a definitive Asset Purchase Agreement ("APA") with VAXIMM AG ("Vaximm") to acquire the full global intellectual property portfolio and related assets for an aggregate purchase price of $30 million.The acquisition follows OSRH's previously announced definitive global exclusive license agreement with BCM Europe AG ("BCME") for VXM01, which includes up to $815 million in milestone payments tied to the development and commercialization of the program.Under the APA, OSRH will acquire the complete VXM01 intellectual property portfolio, including:Global issued and pending patents and patent applicationsProprietary manufacturing know-how and related process technologyRegulatory filings and clinical dataBiological materialsAssigned program-related contracts and agreementsThe VXM01 IP portfolio includes issued and pending patent protection across major global jurisdictions including the United States, Canada, Europe, Japan, China, Korea, and additional territories, with protection extending into 2038."This acquisition advances our strategy of centralizing high-value intellectual property assets at the OSRH parent level," said Peter Hwang, CEO of OSRH. "Under our hub-and-spoke operating model, OSRH acts as the central IP owner, while development and commercialization are executed through affiliated entities and partners. This enhances licensing flexibility and long-term royalty economics, with value accruing to OSRH shareholders."As previously disclosed, OSRH entered into a definitive global exclusive license agreement with BCME on April 29, 2026 relating to the development, commercialization and potential sublicensing of VXM01. Under the agreement:OSRH is eligible to receive up to $815 million in development and commercial milestone paymentsBCME pledged its entire unencumbered OSRH equity stake as collateral for milestone obligationsOSRH retains rights to 100% of downstream royalty economics following BCME cost recovery and preferred return thresholdsOSRH holds a $15 million put option exercisable at $10.00 per share beginning six months after the licensing agreement effective date.Under the terms of the APA, the $30 million purchase price becomes payable upon the first milestone event under the BCME License Agreement, defined as completion of a Phase 2 clinical study (Phase 2b or equivalent trial pending discussions) of VXM01 in either glioblastoma (GBM) or pancreatic ductal adenocarcinoma (PDAC). The agreement also permits OSRH to make voluntary partial payments prior to such milestone event.The centralized IP ownership structure may also facilitate future evaluation of innovative financing and royalty participation structures associated with the VXM01 platform, with additional updates provided as appropriate.About VXM01VXM01 is a clinical-stage oral immunotherapy targeting VEGFR-2, designed to induce a targeted immune response against tumor vasculature and modulate the tumor microenvironment. The program has demonstrated encouraging clinical activity and immune activation in studies in glioblastoma and pancreatic cancer, two of the most difficult to treat solid tumors. VXM01 is being developed by Vaximm AG, a wholly owned subsidiary of OSR Holdings.About OSR HoldingsOSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in health and wellness. Through its subsidiaries, OSR Holdings engages in immuno-oncology, regenerative biologics, and medical device technologies to improve health outcomes worldwide. Learn more at www.OSR-Holdings.comInvestor ContactOSR Holdings, Inc.
Investor Relations
ir@osr-holdings.comForward-Looking StatementsThis press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the anticipated benefits of the transaction, milestone payments, royalty economics, intellectual property rights, future development and commercialization activities relating to VXM01, and the anticipated strategic and financial impact of the transaction. Actual results may differ materially due to various risks and uncertainties, including clinical development risks, regulatory risks, financing risks, commercialization risks and other factors described in the Company's filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements except as required by law.SOURCE: OSR Holdings, Inc.View the original press release on ACCESS NewswireOriginal: OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million Transaction
US Market News
4週前
CEO Statement to ShareholdersMay 12, 2026 9:16 AM
ACCESS NewswireA Clear Commitment: No Reverse Stock SplitBELLEVUE, WA / ACCESS Newswire / May 12, 2026 / As many of our shareholders are aware, OSR Holdings filed its Preliminary Proxy Statement on Schedule PRE 14A with the U.S. Securities and Exchange Commission on May 11, 2026. Given the proximity of our Nasdaq minimum bid compliance deadline, we believe it is important to provide direct and unambiguous transparency regarding our strategy.Notably, the PRE 14A did not include a proposal authorizing a reverse stock split.This was a deliberate decision, and it reflects our firm conviction.We will not pursue a reverse stock split.Management has evaluated this path and rejected it. We believe reverse splits do not create shareholder value. They are structural maneuvers that leave business fundamentals unchanged. We intend to earn our Nasdaq minimum bid compliance back through organic execution, not financial engineering.Committed to Organic Recovery Driven by Subsidiary MilestonesOn April 29, 2026, OSR Holdings executed definitive agreements with BCM Europe AG for the global exclusive license of VXM01, representing up to $815 million in potential milestone payments and marking a major milestone for our oncology platform.In parallel, Woori IO continues to advance its non-invasive glucose monitoring platform through its collaboration with Samsung Electronics, while also progressing discussions under NDA with Sinopharm.These are the kinds of developments that build real, durable shareholder value. We intend to continue delivering on them.Our Position Is ClearManagement is focused entirely on restoring shareholder value through operational execution and strategic milestone delivery. We believe this is the right path forward for our shareholders, for our business, and for the long-term credibility of OSR Holdings as a public company.There will be no reverse split. We believe the market will come to reflect the fundamental value we are building.Commitment to Nasdaq Compliance Through ExecutionManagement remains fully committed to restoring compliance with Nasdaq's minimum bid requirement through the continued delivery of meaningful corporate milestones and disciplined engagement with the investment community - not through structural actions that do not improve our business fundamentals.While there can be no assurance regarding timing or outcomes, we remain fully engaged with our advisors and Nasdaq as we work toward restoring compliance on our own terms.We appreciate the continued support of our shareholders and remain confident in the long-term opportunities ahead for OSR Holdings.Sincerely,Kuk Hyoun "Peter" Hwang
Chief Executive Officer
OSR Holdings, Inc.About OSR Holdings, Inc.OSR Holdings, Inc. (NASDAQ:OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in health and wellness. Through its subsidiaries, OSR Holdings engages in immuno-oncology, regenerative biologics, and medical device technologies to improve health outcomes worldwide. Learn more at www.OSR-Holdings.com.Investor ContactOSR Holdings, Inc.
Investor Relations
ir@osr-holdings.comForward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Nasdaq compliance, strategic transactions, commercialization initiatives, and future business developments. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. OSR Holdings undertakes no obligation to update these statements except as required by law.SOURCE: OSR Holdings, Inc.View the original press release on ACCESS NewswireOriginal: CEO Statement to Shareholders
US Market News
1月前
Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price TargetMay 5, 2026 1:05 PM
ACCESS NewswireNEW YORK, NY / ACCESS Newswire / May 5, 2026 / Emerging Growth Research today issued a flash report on OSR Holdings, Inc. (Nasdaq:OSRH), reaffirming its Buy-Emerging rating and 12-month price target of $10.00.The flash report highlights OSRH's execution of an $815 million definitive exclusive license agreement with BCM Europe AG (BCME) for the global development, commercialization, and out-licensing of VXM01 - a Phase-2b/3 ready oral immunotherapy for glioblastoma multiforme (GBM) and pancreatic cancer. The agreement's specialty-financed structure represents a significant de-risking milestone, with OSRH slated to receive at least $15 million in cash within six months even in a worst-case scenario.Key Highlights from the Flash Report:$815 Million Definitive Exclusive License Agreement with BCME:OSRH executed a definitive exclusive license agreement with BCM Europe AG (BCME) for worldwide development, commercialization, and out-licensing of VXM01. The agreement is structured as an exclusive, global, sublicensable license covering all therapeutic indications and is effective immediately. It is accompanied by a separate Asset Purchase Agreement under which ownership of the VXM01 IP portfolio transfers outright from Vaximm AG to OSRH for $30 million, consolidating IP at the OSRH parent level.Specialty-Financed Structure Provides Significant De-Risking:The agreement's non-traditional structure includes: (1) $815 million in milestone payments to OSRH from BCME, which in turn controls approximately 30% of OSRH shares now collateralized versus an expected $20 million 2026 upfront payment; (2) a protective near-term put entitling OSRH to optionally sell up to $15 million of common stock to BCME at $10.00 per share within six months; and (3) virtually all downstream royalties accruing to OSRH net of BCME's invested capital plus a 15% CAGR threshold return. Together, these terms represent a meaningful de-risking event for shareholders.Woori IO - Named Global Corporate Partners and Commercialization Progress:The Company has attracted impressive named global corporate partners through Woori IO, its non-invasive blood glucose monitoring subsidiary. The combination of the VXM01 licensing deal and continued Woori IO momentum bodes well for management's multi-platform strategy.Share Price Dynamics and Potential Floor:Shares experienced volatility following the announcement of the BCME agreement, only to sharply reverse on short covering. Emerging Growth Research believes a share price floor of approximately $0.40-$0.45 may now be in place, providing a risk-asymmetric entry point for investors.Key Risks and Near-Term Milestones:Risks remain, including OSRH's limited operating history, the early-stage nature of its development programs, and the potential that licensing deal milestones may not be fully realized. Near-term milestones include execution of the Asset Purchase Agreement within the 30-day contractual window and BCME's progress toward a licensee agreement with a major pharmaceutical partner. Potential dilution via an equity line of credit and exercise of the protective put option is also noted.For a copy of the full flash report, please visit:[LINK HERE FOR PDF REPORT]orhttps://emerginggrowth.com/profile/osrh/ (on the right side of the page as you scroll down)About OSR Holdings, Inc.Founded in 2020 and headquartered in Bellevue, Washington and Gyeonggi-do, South Korea, OSR Holdings, Inc. (Nasdaq:OSRH) is a global healthcare holding company with operations in Korea and Switzerland. The Company has four wholly owned subsidiaries developing oral immunotherapies for the treatment of cancer and biologics for age-related and other degenerative diseases, as well as a diabetes-focused medical device developer advancing non-invasive glucose monitoring technology. OSRH also distributes medical devices and systems and is expanding into 4th party logistics (4PL).About Emerging Growth ResearchEmerging Growth Research is an independent equity research firm providing institutional-quality analysis on emerging and growth-stage companies. The firm delivers ongoing coverage, including Flash Reports on material developments, designed to enhance transparency and broaden investor awareness for companies participating in the Emerging Growth Conference platform.Contact:Emerging Growth Research
Research@EmergingGrowth.com
www.EmergingGrowth.comForward-Looking StatementsThis press release contains forward-looking statements concerning business operations and financial performance as well as plans, objectives, and expectations for OSR Holdings, Inc. that are subject to risks and uncertainties. These statements include, but are not limited to, expectations regarding licensing agreements, regulatory pathways, product development, and capital formation. Actual results may differ materially due to a variety of risks, including the possibility that non-binding agreements do not result in definitive transactions, that licensing deal milestones may not be realized, regulatory challenges, potential dilution from future financing activities, and financing constraints. SOURCE: OSR Holdings, Inc.View the original press release on ACCESS NewswireOriginal: Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target
US Market News
1月前
OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026April 30, 2026 9:15 AM
ACCESS NewswireOSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026BELLEVUE, WA / ACCESS Newswire / April 30, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding company advancing biomedical innovations to improve health and wellness worldwide, today announced that management will present at the upcoming Emerging Growth Conference. The presentation will provide investors and analysts with an overview of the Company's landmark VXM01 global licensing agreement and its implications for OSRH shareholders.Virtual Presentation DetailsDate: May 7, 2026Time: 4:10 p.m. ETFormat: VXM01 Licensing Overview and Q&ARegistration: https://goto.webcasts.com/starthere.jsp?ei=1755070&tp_key=280dc3ffe3&sti=oshrTim Smith, Head of Investor Relations, will give an in-depth view of the recently executed VXM01 global licensing agreement, followed by a Q&A session. Investors are encouraged to submit questions in advance to Questions@EmergingGrowth.com or during the live event and management will address as many questions as possible.Attendees are encouraged to register in advance. For those unable to attend live, an archived webcast will be available at EmergingGrowth.com, the Emerging Growth YouTube Channel, and in the "Events & Presentations" section of the Company's website OSR-Holdings.com.To view the Company's previous presentation, visit:https://www.youtube.com/watch?v=n7CjcvlFVzw&t=377sAbout the Emerging Growth ConferenceThe Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.All sessions will be conducted through video webcasts and will take place in the Eastern time zone.About OSR HoldingsOSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in health and wellness. Through its subsidiaries, OSRH engages in immuno-oncology, regenerative biologics, and medical device technologies to improve health outcomes worldwide. Learn more at www.OSR-Holdings.com.Investor ContactOSR Holdings, Inc.
Investor Relations
ir@osr-holdings.comForward-Looking StatementsThis press release contains forward-looking statements within the meaning of applicable U.S. securities laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including those described in the Company's filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements, except as required by law.SOURCE: OSR Holdings, Inc.View the original press release on ACCESS NewswireOriginal: OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026
US Market News
1月前
OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM EuropeApril 29, 2026 9:50 AM
ACCESS NewswireLargest shareholder pledges entire equity stake as collateral for milestone obligations, reinforcing alignment with public shareholdersBELLEVUE, WA / ACCESS Newswire / April 29, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) today announced that it has entered into a definitive global exclusive license agreement (the "Agreement") with BCM Europe AG ("BCME") for the development, commercialization, and potential sublicensing of VXM01, its Phase 3-ready oral immunotherapy targeting VEGFR-2.The Agreement builds on the previously disclosed binding term sheet and establishes a structured framework to advance VXM01, with alignment across OSRH, its largest shareholder BCME, and public shareholders."This agreement establishes a clear, accountable framework for the development of VXM01," said Peter Hwang, CEO of OSRH. "It ensures OSR Holdings shareholders participate directly in value creation, while BCME remains accountable for its financial commitments."Transaction OverviewLicense: BCME receives an exclusive global license to develop, manufacture, commercialize, and sublicense VXM01Milestones: OSRH to receive up to $815 million in milestone payments tied to clinical, regulatory, and commercial achievementsIP Ownership: OSRH to acquire full VXM01 IP from Vaximm AG under a $30 million asset purchase agreementRoyalties: OSRH to receive 100% of downstream royalties after BCME recovers its investment and preferred returnSecurity: BCME and affiliates pledge 100% of their OSRH shares as collateral for milestone obligationsGoverning Law: Switzerland (Canton of Basel)BCME is the Company's largest shareholder. Accordingly, the Agreement constitutes a related party transaction and was approved by the Board, including independent directors, following consideration of an independent fairness opinion provided by Avance Life Sciences.Taken together, these economics position OSRH to capture the long-term value created through VXM01's development and commercialization.Alignment Through Equity PledgeUnder a separate Pledge Agreement, BCME and affiliates have pledged their entire unencumbered shareholding in OSRH, representing approximately 29.7% as of the signing date, as collateral for the performance of milestone payment obligations of up to $815 million. This structure is designed to:Provide assurance of BCME's financial commitments under the AgreementAlign the economic interests of the largest shareholder with those of public shareholdersSupport milestone performance through a collateral-backed mechanism under the Pledge Agreement"The decision by BCME to pledge its entire stake as collateral reflects strong conviction in the clinical and commercial potential of VXM01," said Tim Smith, Head of Investor Relations. "It aligns all shareholders around advancing this program toward commercialization and delivering meaningful new treatment options to patients."BCME will actively support development of VXM01 and at the same time engage leading global pharmaceutical partners to secure a sublicensing transaction. With economic returns dependent on downstream monetization and its entire OSRH stake pledged as collateral, BCME is structurally incentivized to advance VXM01 and execute a competitive partnering process focused on maximizing value for OSRH shareholders.Additional Value Mechanism: Put OptionThe Agreement also includes a put option under which OSRH may require BCME to purchase up to $15 million of OSRH common stock at a price of $10.00 per share, exercisable no earlier than six months following the effective date. This feature provides additional capital flexibility and further underscores BCME's long-term commitment to OSRH.About VXM01VXM01 is a clinical-stage oral immunotherapy targeting VEGFR-2, designed to induce a targeted immune response against tumor vasculature and modulate the tumor microenvironment. The program has demonstrated encouraging clinical activity and immune activation in studies in glioblastoma and pancreatic cancer, two of the most aggressive and treatment-resistant solid tumors. VXM01 is being developed by Vaximm AG, a wholly owned subsidiary of OSR Holdings.About BCM Europe AGBCM Europe AG is a Switzerland-based life sciences investment entity and the largest shareholder of OSR Holdings.About OSR HoldingsOSR Holdings, Inc. (NASDAQ:OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in health and wellness. Through its subsidiaries, OSR Holdings engages in immuno-oncology, regenerative biologics, and medical device technologies to improve health outcomes worldwide. Learn more at www.OSR-Holdings.com.Investor ContactOSR Holdings, Inc.
Investor Relations
ir@osr-holdings.comForward-Looking StatementsThis press release contains forward-looking statements, including statements regarding expected development, milestone payments, sublicensing activities, and the potential benefits of the Agreement. These statements are subject to risks and uncertainties, including clinical, regulatory, and market risks, and actual results may differ materially. OSR Holdings undertakes no obligation to update forward-looking statements except as required by law.SOURCE: OSR Holdings, Inc.View the original press release on ACCESS NewswireOriginal: OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe
US Market News
2月前
OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible NoteApril 9, 2026 9:15 AM
ACCESS NewswireBELLEVUE, WA / ACCESS Newswire / April 9, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) ("OSR Holdings" or the "Company") today announced a strategic transaction for capital structure optimization with White Lion GBM Innovation Fund ("White Lion"), centered on the retirement of approximately $2.02 million of warrant overhang.Elimination of $2.02 Million Warrant OverhangAs part of the transaction, OSR Holdings has retired approximately $2.02 million of outstanding warrants by consolidating them into a newly issued convertible promissory note.The Company issued a $555,555 convertible note to secure near-term liquidity to support general corporate purposes and the continued execution of strategic priorities.In connection with the warrant retirement, the extinguished warrants were effectively incorporated into the note, bringing the total face value of the instrument to $1,055,555.This structure enables OSR Holdings to eliminate a substantial source of potential dilution at a significant discount to the prior overhang value, representing a highly efficient balance sheet optimization.Premium Conversion Price at $1.00 per ShareThe convertible note is structured with a fixed conversion price of $1.00 per share, representing approximately a 100% premium to the Company's most recent closing price of approximately $0.49 on April 8, 2026.The premium conversion price reflects a shared alignment with long-term shareholder value and stands in contrast to conventional discounted convertible structures.The $1.00 level is also strategically aligned with the Company's objective of maintaining compliance with NASDAQ minimum bid requirements.Six-Month Conversion RestrictionThe note was issued as a private placement without a registration statement:Accordingly, the note includes a six-month restriction on conversion, ensuring that no shares may be issued into the public float during this period.This feature further supports near-term trading stability by preventing immediate dilution following the transaction.Management Commentary"This transaction is fundamentally about removing structural overhang and strengthening our equity story," said Peter Hwang, CEO of OSR Holdings. "By retiring over $2 million in warrant overhang into a tightly structured instrument, we are meaningfully cleaning up our cap table. Furthermore, the $1.00 conversion price and six-month restriction demonstrate a shared commitment by our investor to stabilizing our valuation as we focus on regaining NASDAQ minimum bid compliance."The Company believes this transaction represents a meaningful step in optimizing its capital structure, removing technical barriers to equity performance, and securing near-term capital to advance its strategic priorities across its immunotherapy, degenerative disease, and medtech platforms.Further details regarding this transaction will be included in the Company's filings with the U.S. Securities and Exchange Commission.About White Lion GBM Innovation FundThe White Lion GBM Innovation Fund, one of Innovate GBM's core sponsors, focuses on strategic funding opportunities in glioblastoma drug development. The Innovation Fund leverages the ecosystem curated by Innovate GBM to gain insights from the GBM community-including neuro-oncologists, scientists, and patient advocacy groups-to guide capital allocation toward the most impactful opportunities.About OSR Holdings, Inc.OSR Holdings, Inc. (NASDAQ:OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in health and wellness. Through its subsidiaries, OSRH engages in immuno-oncology, regenerative biologics, and medical device technologies to improve health outcomes worldwide. Learn more at www.OSR-Holdings.com.Investor ContactOSR Holdings, Inc.
Investor Relations
ir@osr-holdings.comForward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable U.S. securities laws, including statements regarding the Company's capital structure, liquidity, and expected benefits of the financing. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including those described in the Company's filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements, except as required by law.SOURCE: OSR Holdings, Inc.View the original press release on ACCESS NewswireOriginal: OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note
KeepItRealistic
2月前
$OSRH DD is your friend 👇
what is BCME goals in its funding strategy for Vaximm
BCM Europe AG (BCME) is a Switzerland-based life sciences investment entity that functions primarily as a development-stage biotech financier and licensing intermediary. Core Goals and Business ModelIts main objective in deals like the VXM01 transaction is to act as a bridge between early-stage biotech assets (often from smaller companies or subsidiaries) and larger pharmaceutical partners.
Specifically:• Bridge development and de-risk assets: BCME takes on assets like VXM01, funds or supports further clinical development (via dedicated investment vehicles/funds), and advances them to a point where they can be out-licensed to a major pharma company for global commercialization.
• Generate returns through milestones and royalties: By licensing in assets with high potential (e.g., up to $815M milestones + royalties in the OSRH/Vaximm deal), they aim to capture upside from successful development milestones, regulatory approvals, and commercial sales while passing through economics (with recovery mechanisms) to stakeholders.
• Leverage specialized vehicles: They establish dedicated funds (e.g., the tentatively named BCM Decentralized Science Investors I, LP) anchored by strategic investors. These vehicles handle the licensing, development financing, and eventual partnering.
In short, BCME’s strategy focuses on value creation through active intermediation — providing capital, operational support, and partnering expertise to accelerate programs that might otherwise struggle for funding or visibility, while aligning with its position as OSRH’s largest shareholder. This model reduces risk for the original biotech owners (by offloading late-stage costs) and creates multiple return pathways for BCME’s investors.
Note that public information on BCME is limited mostly to press releases and SEC filings tied to OSRH/Vaximm; it does not appear to have a highly visible independent website or broad portfolio disclosures. This structure is common for niche Swiss life sciences investment groups focused on targeted, high-upside deals rather than broad public marketing.
This fits the ongoing OSRH deal well — BCME is stepping in to fund/advance VXM01 toward a bigger pharma exit.
KeepItRealistic
2月前
$OSRH $815 million binding term sheet details
https://www.sec.gov/Archives/edgar/data/1840425/000121390026039691/ea028505701ex10-1.htm
It’s a binding term sheet, with a final executed license agreement targeted for late April 2026.
BCM Europe is already a major shareholder, suggesting alignment. Milestones (if hit) could be transformative for a company this size. Recent analyst coverage (e.g., Emerging Growth Research) has been bullish with high price targets.
The core economics (milestones and development support) involve no immediate equity issuance or heavy dilution. The $15M equity option is optional for OSR, at a premium price ($10/share vs. current ~$0.55), and would only happen if the company chooses it for funding. This limits involuntary dilution compared to typical PIPEs, convertibles, or ATM offerings at market prices.
If exercised, it would add shares (roughly 1.5M at $10), which is material but at favorable terms.
This looks like a strategic, potentially high-upside licensing move designed to minimize dilution and bring value to the parent level.
US Market News
2月前
Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price TargetMarch 27, 2026 9:00 AM
ACCESS NewswireNEW YORK CITY, NY / ACCESS Newswire / March 27, 2026 / Emerging Growth Research today issued a flash report on OSR Holdings, Inc. (Nasdaq:OSRH), reaffirming its Buy-Emerging rating and 12-month price target of $10.00.The flash report highlights recent developments related to the Company's non-invasive glucose monitoring technology (Woori IO), including increasing global interest in potential licensing and distribution opportunities.Key Highlights from the Flash Report:Global Licensing Interest in Woori IO:OSRH recently announced interest from multiple regions, including Japan, Korea, India, Israel, and the United States, for its non-invasive glucose monitoring technology. The Company is exploring potential licensing and distribution pathways as part of its broader commercialization strategy.NDA Signed with Sinopharm:OSRH has entered into a non-disclosure agreement with Sinopharm, a large Chinese state-owned pharmaceutical and distribution company. The agreement facilitates information exchange related to regulatory, clinical, and commercial pathways for Woori IO within the Chinese diabetes care market.Additional Validation of Strategic Direction:The announcement represents a second notable development in recent months, following the previously disclosed licensing term sheet with BCM Europe AG (BCME) for VXM01. Together, these developments support management's ongoing efforts to advance both its therapeutic and medical device platforms.Potential Near-Term Milestones:The Company is expected to work toward a definitive agreement with BCME related to the VXM01 licensing structure, which carries a potential milestone value of up to $815 million. The updated deal structure is intended to position OSRH as the primary counterparty.Positioning for Capital Formation:Management continues to engage with institutional investors, and the evolving licensing framework may support future capital raising efforts.Emerging Growth Research notes that while these developments are constructive, risks remain, including the early-stage nature of certain programs, the non-binding status of some agreements, and potential dilution from future financing activities.For a copy of the full flash report, please visit:https://emerginggrowth.com/wp-content/uploads/2026/03/OSRH_Flash-Report_03.26.26.pdforhttps://emerginggrowth.com/profile/osrh/ (on the right side of the page as you scroll down)About OSR Holdings, Inc.Founded in 2020 and headquartered in Bellevue, Washington and Gyeonggi-do, South Korea, OSR Holdings, Inc. (Nasdaq:OSRH) is a global healthcare holding company with operations in Korea and Switzerland. The Company has subsidiaries focused on the development of oral immunotherapies for cancer, biologics for degenerative diseases, and non-invasive glucose monitoring technology. OSRH also distributes medical devices and is expanding into 4th party logistics (4PL).Contact:Emerging Growth Research
Research@EmergingGrowth.com
www.EmergingGrowth.comForward-Looking StatementsThis press release contains forward-looking statements concerning business operations and financial performance as well as plans, objectives, and expectations for OSR Holdings, Inc. that are subject to risks and uncertainties. These statements include, but are not limited to, expectations regarding licensing agreements, regulatory pathways, product development, and capital formation. Actual results may differ materially due to a variety of risks, including the possibility that non-binding agreements do not result in definitive transactions, regulatory challenges, and financing constraints. SOURCE: OSR Holdings, Inc.View the original press release on ACCESS NewswireOriginal: Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target
US Market News
2月前
OSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent LevelMarch 23, 2026 8:30 AM
ACCESS NewswireBELLEVUE, WA / ACCESS Newswire / March 23, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) today announced an updated structure of its previously disclosed binding term sheet dated January 13, 2026 with BCM Europe AG for the global licensing of its lead oncology asset VXM01. The revised structure is designed to improve capital efficiency and shift economic benefits directly to the parent company, OSR Holdings and its shareholders.Under the new framework, OSR Holdings will become a direct counterparty to the licensing agreement alongside its Swiss subsidiary, Vaximm AG, and an investment vehicle sponsored by BCM Europe AG. As part of this restructuring, up to $815 million in milestone payments, excluding royalties, will be payable directly to OSR Holdings rather than at the subsidiary level, reducing reliance on upstream distributions and simplifying the flow of funds.In parallel, OSR Holdings will provide a development financing facility of up to $30 million to Vaximm AG, which may be drawn as needed to support clinical development of VXM01. This replaces the previous structure in which upfront payments were made directly by the BCME-sponsored fund to the subsidiary. The drawdown structure allows Vaximm to access capital in line with actual clinical program needs, improving capital efficiency across the organization.The revised structure is expected to enhance value for OSR Holdings shareholders through:Direct parent-level value capture from milestone and royalty paymentsReduced reliance on subsidiary-level distributions, simplifying the flow of fundsImproved capital efficiency through drawdown-based development fundingCentralized control over capital allocation at the OSR Holdings level"This revised structure enables us to capture the full economic potential of VXM01 at the OSR Holdings level while funding its development in a disciplined, capital-efficient way," said Peter Hwang, CEO of OSR Holdings. "We believe it positions us to translate clinical progress more directly into shareholder value, which is critical as we advance VXM01 into later-stage development."OSR Holdings also retains an option to issue up to $15 million of common stock to the BCME fund at $10 per share, exercisable six months after execution of the definitive agreement at OSR Holdings' sole discretion. The stated issuance price, set above recent trading levels, reflects alignment around the long-term value potential of VXM01 and provides additional financing flexibility while maintaining control over timing and potential dilution.Provisions for digital asset financing, which had been contemplated in the prior term sheet, have been deferred by mutual agreement pending further regulatory clarity applicable to public companies holding and transacting in digital assets. The Parties reserve the right to reintroduce such provisions in a future amendment once the regulatory environment is sufficiently defined.The April 30, 2026 target date for execution of a definitive agreement remains unchanged, subject to board approval and an independent fairness opinion. VXM01 is an oral DNA-based immunotherapy targeting VEGFR-2 and is positioned for late-stage clinical development in oncology.Key TakeawaysDirect value capture: Milestones and royalties payable directly to OSRHTotal deal size: Up to $815M in milestones, excluding royaltiesUpfront restructured: $30M development facility to Vaximm, drawable as neededEquity option: $15M at $10/share, exercisable 6 months after execution at OSRH's sole discretionDigital assets: Deferred pending regulatory clarity for public companiesTarget signing: Definitive agreement expected by April 30, 2026About OSR Holdings, Inc.OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in healthcare and wellness. Through its subsidiaries, OSRH engages in immuno-oncology, regenerative biologics, and medical device technologies to improve global health outcomes. Learn more at www.OSR-Holdings.com.About Vaximm AGVaximm AG is a privately held Swiss-German biotechnology company and a wholly owned subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH). Vaximm's proprietary orally administered T-cell vaccination platform harnesses live, attenuated bacterial vectors to deliver tumor-associated antigens, inducing robust cellular immune responses. Lead candidate VXM01, targeting VEGFR-2, has demonstrated clinical activity and safety in multiple cancer indications. Learn more at www.Vaximm.com.About BCM Europe AGBCM Europe AG is a Switzerland-based life sciences investment entity and the largest shareholder of OSR Holdings.Media & Investor ContactOSR Holdings, Inc.
Investor Relations
ir@osr-holdings.comForward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential licensing agreement between Vaximm AG and BCM Europe AG, the development and commercialization of VXM01, the expected benefits of the revised transaction structure, and the anticipated timing of execution of a definitive agreement. These statements are subject to risks and uncertainties, including, but not limited to, the ability of the parties to finalize definitive agreements, the timing and success of clinical development, regulatory developments, market conditions, and other factors that may affect the Company's business and financial condition. Actual results may differ materially from those expressed or implied. OSR Holdings, Vaximm, and BCM Europe AG undertake no obligation to update these forward-looking statements, except as required by law.SOURCE: OSR Holdings, Inc.View the original press release on ACCESS NewswireOriginal: OSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent Level
US Market News
3月前
Woori IO, an OSR Company, Signs NDA with Sinopharm for China Market and Global Multicenter TrialsMarch 19, 2026 9:44 AM
PR Newswire (US)
BELLEVUE, Wash., March 19, 2026 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a healthcare-focused holding company advancing innovative medical technologies, today announced that its subsidiary, Woori IO Co., Ltd. ("Woori IO"), has entered into a mutual non-disclosure agreement ("NDA") with Sinopharm Group Beijing Huahong ("Sinopharm"), the Beijing-based unit of Sinopharm Group and major state-owned healthcare and pharmaceutical distribution enterprise of China. This announcement is being made in accordance with Regulation FD to ensure broad, non-exclusionary public dissemination of this information.
The NDA establishes a formal framework for Woori IO and Sinopharm to exchange confidential information relating to Woori IO's noninvasive near-infrared (NIR) glucose monitoring technology, allowing both parties to evaluate potential regulatory, clinical, and commercial pathways in China. Sinopharm Group, with reported 2024 revenue of approximately USD 81 billion, is generally considered China's largest pharmaceutical and medical device distributor with the most extensive nationwide network.China represents one of the world's largest and fastest-growing diabetes markets, with more than 140 million people estimated to be living with the disease and rising demand for convenient glucose monitoring solutions. China's diabetes device market is projected to expand significantly over the next decade, potentially exceeding $12 billion by 2032, according to a report by Research and Markets, as adoption of advanced glucose monitoring technologies accelerates. Woori IO's proprietary NIR optical sensing technology addresses this demand directly, offering noninvasive, needle-free continuous glucose monitoring without the pain and adoption barriers of conventional invasive methods."China is a highly compelling market, given its large and growing diabetes population and increasing adoption of advanced glucose monitoring technologies," said Peter Hwang, CEO of OSR Holdings. "Our engagement with Sinopharm reflects the strategic importance of the China market and the potential role that established national distribution platforms may play in enabling future commercialization. While still at an early stage, this engagement underscores the broader global interest in Woori IO's noninvasive glucose monitoring platform."Woori IO has received additional interest from healthcare organizations, pharmaceutical companies, and distribution partners across multiple regions, highlighting growing recognition of its noninvasive glucose monitoring platform and strong demand for more accessible, patient-friendly solutions. "Our NDA with Sinopharm allows us to begin evaluating potential regulatory and commercial pathways in China while continuing discussions with partners in other regions," said Sunkie Park, CEO of Woori IO. "These interactions could help shape future clinical development programs, including potential global multicenter trials."While discussions remain preliminary, OSR Holdings intends to actively pursue strategic partnerships across major international markets as it advances development, regulatory strategy, and potential commercialization pathways for this next-generation glucose monitoring technology, which could represent a transformational step forward in improving accessibility and convenience in diabetes care globally.About OSR Holdings, Inc.OSR Holdings, Inc. (NASDAQ:OSRH) is a global healthcare holding company dedicated to advancing biomedical innovation approaches to health and wellness. Through its subsidiaries, OSRH is engaged in immuno-oncology, regenerative biologics, and medical device technologies. Its vision is to build a portfolio of breakthrough healthcare solutions to improve global health outcomes. Learn more at www.OSR-Holdings.com.About Woori IO Co., Ltd.Woori IO is a South Korea-based medical device company developing noninvasive biosensing technologies for glucose monitoring and beyond. Its proprietary NIRS-based system enables accurate, pain-free glucose tracking and is designed for integration into wearables. The company has been recognized by a leading global consumer electronics company's startup program for its innovation in NIGM technology. Learn more at www.woori.io.Contact:Media & Investor Contacts
OSR Holdings, Inc.
Investor Relations
ir@osr-holdings.comForward-Looking StatementsThis press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding potential collaboration opportunities, anticipated commercialization pathways, regulatory strategy, global market demand for noninvasive CGM technology, and future business prospects. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Factors that may affect future results include, but are not limited to, the ability to enter into definitive agreements with prospective partners, regulatory approvals, product development outcomes, market acceptance, competitive developments, capital market conditions, and other risks described in OSR Holdings' filings with the U.S. Securities and Exchange Commission. OSR Holdings undertakes no obligation to update forward-looking statements except as required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/woori-io-an-osr-company-signs-nda-with-sinopharm-for-china-market-and-global-multicenter-trials-302718811.htmlSOURCE OSR Holdings
Original: Woori IO, an OSR Company, Signs NDA with Sinopharm for China Market and Global Multicenter Trials
US Market News
3月前
OSR Holdings, Inc. Granted 180-Day Nasdaq Extension; Reaffirms Strategic MomentumMarch 5, 2026 9:30 AM
ACCESS NewswireBELLEVUE, WASHINGTON / ACCESS Newswire / March 5, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding company advancing innovative biomedical technologies, today announced that it has received written notification from The Nasdaq Stock Market LLC granting the Company an additional 180-calendar-day extension to regain compliance with Nasdaq Listing Rule 5550(a)(2), the minimum $1.00 bid price requirement for continued listing on the Nasdaq Capital Market.The extension provides the Company until August 31, 2026, to satisfy the rule by achieving a closing bid price of at least $1.00 per share for ten consecutive business days. There is no immediate effect on the listing or trading of the Company's common stock, which will continue to trade on the Nasdaq Capital Market under the ticker symbol "OSRH."Strategic Continuity and ExecutionAs outlined in the CEO's February 2026 Statement to Shareholders, the Company remains focused on strengthening its capital structure and advancing near-term value catalysts, including:VXM01 Licensing Initiative: Subsidiary Vaximm AG continues to advance discussions toward a global licensing transaction for lead immuno-oncology asset VXM01, structured to include USD 30 million in upfront consideration (USD 15 million cash and USD 15 million digital assets) and up to USD 815 million in milestone payments.Medical Device Platform Merger: Progressing consolidation of RMC and Woori IO to form an integrated medical technology and distribution platform, while advancing international partnership interest in Woori IO's non-invasive glucose monitoring technology.In its prior disclosure regarding the minimum bid price deficiency, the Company noted unusual trading dynamics impacting its share price. While management continues to monitor market activity and safeguard shareholder interests, the Company believes that disciplined execution of its strategic initiatives and continued strengthening of underlying fundamentals represent the most effective path to enhancing long-term shareholder value."We view this extension as a clear operational runway for our strategic initiatives to mature and translate into tangible shareholder value," said Tim Smith, Head of Investor Relations. "With multiple near-term catalysts advancing, we believe OSR Holdings is well positioned to strengthen its capital markets profile and return to compliance through disciplined execution."The Company will continue to monitor its bid price closely and remains confident in its ability to execute its strategic initiatives and restore full compliance during the extension period.About OSR Holdings, Inc.OSR Holdings is a healthcare-focused holding company dedicated to accelerating innovation across immuno-oncology, regenerative biologics, and medical technologies. Through strategic investment and operational oversight, the Company seeks to develop and commercialize transformative healthcare solutions while maintaining a strong commitment to corporate governance and long-term shareholder value. Learn more at www.OSR-Holdings.comContactMedia & Investor Contacts
OSR Holdings, Inc.
Investor Relations
Email: ir@osr-holdings.com Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the Company's ability to regain compliance with Nasdaq listing requirements; the timing, structure, and potential completion of any licensing transaction involving VXM01; anticipated upfront or milestone consideration (including digital asset components); and the execution of the Company's strategic initiatives. These forward-looking statements involve risks and uncertainties, including market conditions, regulatory developments, transaction execution risk, volatility in digital asset markets, and other factors that could cause actual results to differ materially from those expressed or implied. The Company undertakes no obligation to update any forward-looking statements except as required by law.SOURCE: OSR Holdings, Inc.View the original press release on ACCESS NewswireOriginal: OSR Holdings, Inc. Granted 180-Day Nasdaq Extension; Reaffirms Strategic Momentum
US Market News
4月前
CEO Statement to ShareholdersFebruary 2, 2026 9:50 AM
ACCESS NewswireBELLEVUE, WASHINGTON / ACCESS Newswire / February 2, 2026 / Reaffirming Strategic Execution and Long-Term Value CreationAs the compliance deadline under the minimum bid requirement of NASDAQ approaches, we recognize that market volatility and uncertainty can weigh on investor sentiment. Periods like this often test confidence, particularly for innovation-driven companies that are building long-term value rather than optimizing for short-term optics.I want to take this opportunity to reaffirm that the fundamentals of OSR Holdings, Inc. remain strong, and that the management team is firmly focused on executing against clearly defined value-creating milestones.Progress on VXM01 LicensingOur Swiss biotech subsidiary, Vaximm AG, continues to make solid progress toward finalizing the global licensing transaction for its lead asset, VXM01. Based on the Binding Term Sheet recently executed with BCM Europe AG, the contemplated transaction structure includes:Up to USD 815 million in development, regulatory, and commercial milestonesUSD 30 million upfront consideration, consisting of USD 15 million in cash and USD 15 million in digital assetsWhile the definitive agreement remains subject to customary conditions, diligence, and final documentation, discussions are advancing constructively and in line with the economic framework already disclosed. We view this potential licensing transaction as a meaningful validation of VXM01's platform value and of OSR Holdings' hub-and-spoke biotech strategy.Strategic Review of Medical Device Platform MergerIn parallel, we are encouraged by the ongoing strategic discussions between our two medical device subsidiaries, RMC and Woori IO. Management teams from both companies are actively working toward a potential term sheet for a merger of the two entities.The strategic rationale for this combination has strengthened further in light of recent regulatory clarity from the U.S. Food and Drug Administration regarding the oversight of non-medical-grade consumer wearable devices. This clarification enables Woori IO to pursue a dual-track commercialization strategy:Consumer wearable products positioned as lifestyle and wellness management tools, which may be commercialized independently of medical-device regulatory approvalsMedical-grade non-invasive continuous glucose monitoring (CGM) devices, which will continue to progress through the appropriate regulatory pathwaysAs a result of this improved regulatory visibility, Woori IO has recently begun receiving proactive inbound interest from global device distributors, including potential partners prepared to act as importers and local agencies across key international markets. The company aims to announce formal distribution engagements in due course.When combined with RMC's established, cash-flow-generating operating platform, we believe Woori IO's differentiated technology and expanded commercial optionality create a compelling foundation for growth. Upon consummation of such merger, the combined entity will be evaluated with a view toward a Korean listing, with consideration given to the growth-oriented KOSDAQ market which has recently reached its highest index level in approximately 25 years.Looking AheadOSR Holdings was built to create value through disciplined capital allocation, strategic partnerships, and the maturation of differentiated healthcare technologies. Short-term market dynamics do not change that mission, nor do they alter the intrinsic value we believe is being created across our portfolio.Management remains fully engaged with regulators, partners, and advisors to address listing requirements in accordance with applicable Nasdaq rules while continuing to advance transactions that we believe can unlock substantial shareholder value. We appreciate the continued support and patience of our investors as we execute on these priorities.Sincerely,Kuk Hyoun "Peter" Hwang
Chief Executive Officer
OSR Holdings, Inc.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding potential transactions, regulatory pathways, commercialization strategies, anticipated milestones, and future announcements. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. OSR Holdings undertakes no obligation to update forward-looking statements except as required by law.About OSR Holdings, Inc.OSR Holdings, Inc. (NASDAQ:OSRH) is a global healthcare holding company dedicated to advancing biomedical innovation approaches to health and wellness. Through its subsidiaries, OSRH is engaged in immuno-oncology, regenerative biologics, and medical device technologies. Its vision is to build a portfolio of breakthrough healthcare solutions to improve global health outcomes. Learn more at www.OSR-Holdings.com.CONTACT:Media & Investor Contacts
OSR Holdings, Inc.
Investor Relations
ir@osr-holdings.comSOURCE: OSR Holdings, Inc.View the original press release on ACCESS NewswireOriginal: CEO Statement to Shareholders
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
glenn1919
4週前
Zorro
4週前
hondaboost
1月前
Zardiw
1月前
stressfreeliving
2月前
メールアドレスで登録
